SaVia Health Raises $8.5 Million Seed Round to Optimize Patient Care Pathways
SaVia Health, a clinician-led healthcare SaaS company that creates and embeds patient care processes alongside electronic medical records (EMR), announced it raised an $8.5 million Seed round. The round was led by Intel Capital with participation from Kickstart, Peterson Ventures, Tom Burton, the founder of Health Catalyst, and Dr. Brent James, a professor at Stanford and renowned luminary in the healthcare quality improvement field.
SaVia Health was founded by a clinician, Dr. Will Caldwell, and a group of veteran healthcare software engineers led by David Edwards based in Salt Lake City, UT, seeking to provide clinicians with the ability to self-author clinical care pathways and provide clinical advice at the point of care.
“When I first saw clinicians using the SaVia tools, I knew the platform was something special. Never in my 21 years of clinical practice have I seen a piece of technology so fiercely embraced by clinicians,” said Dr. Will Caldwell, co-founder and CEO of SaVia Health. “Clinicians can finally design, implement, and modify care processes in a way that mirrors the rapidly evolving clinical landscape.”
“SaVia is a game changer when it comes to process redesign that enables deep operational and clinical improvement,” said Tom Burton, co-founder and Strategic Advisor of Health Catalyst. “With SaVia, dynamic workflow data capture changes can be made in minutes rather than weeks or months accelerating the speed of process improvement.”
Today, SaVia Health provides clinicians and administrators with a versatile software tool that transforms paper-based care processes into digital workflows, embedding them directly into the EMR. As a result, clinicians have real-time clinical advice at their fingertips. By standardizing care along best practice guidelines, mistakes are avoided and patients achieve better outcomes.
“Intermountain [Healthcare] caregivers have been using SaVia’s technology for years to provide the best possible care to our patients. SaVia’s tools enable front-line caregivers to consistently deliver best practices as part of their clinical workflows,” said Raj Srivastava, Senior Medical Executive Director at Intermountain Healthcare Delivery Institute. “We are thrilled to continue partnering with SaVia as an independent company to continue improving patient outcomes.”
“Patient care faces several challenges, including smoothly integrating the latest technology into existing processes,” said Nick Washburn, Senior Managing Director at Intel Capital. “SaVia is seamlessly changing the game for clinicians by translating data into guidance on what steps to take and when to best serve each patient.”
With this funding round, the company will further develop the self-authoring platform, expand its existing library of off-the-shelf applications, and focus on rapidly driving sales.
About SaVia Health
SaVia Health is a healthcare technology company based in Salt Lake City, UT that provides SaaS based process improvement software targeted at health systems, self-insured corporations, and large physician groups both in the United States and abroad. To learn more, visit saviahealth.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221212005152/en/
Contact information
Sam Taylor
EVP of Sales and Marketing
sam.taylor@saviahealth.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom